Drugs / amphotericin B deoxycholate
amphotericin B deoxycholate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04072640 | Jan 2021 → Jul 2022 | Cryptococcal meningitis, HIV infectious disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06447402 | Jun 2024 → May 2027 expected | pulmonary aspergilloma | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT00361517 | Jun 2006 → Oct 2007 | aspergillosis | Singapore General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00003031 | Jun 1997 → Oct 2000 | infectious disease | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT01310738 | Feb 2011 → Oct 2014 | visceral leishmaniasis | University of Brasilia | Terminated | Missed primary |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT01945281 Comparator | Jan 2014 → Jan 2018 | candidiasis, invasive | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00815516 Comparator | Feb 2013 → Dec 2014 | candidiasis | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00696969 Comparator | Jun 2008 → Jan 2010 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | Met primary |
| Phase 3 | NCT00628719 Comparator | Feb → Aug 2008 | visceral leishmaniasis | Banaras Hindu University | Completed | Met primary |
| Phase 3 | NCT00523965 Comparator | Sep 2007 → Aug 2009 | visceral leishmaniasis | Banaras Hindu University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amphotericin B deoxycholate | “Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)” NCT04072640 ↗ |
| Known as | AmB-D | “Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC).” PMID 29596222 ↗ Oct 2018 |
| Known as | dAMB | “intravenous 1 mg/kg amphotericin B deoxycholate (dAMB)” PMID 31586424 ↗ Jan 2020 |
| Route | Intravenous | “Patients receive intravenous amphotericin B daily” NCT00003031 ↗ |